Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
about
Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Safety and Efficacy of B-domai ...... -marketing Surveillance Study.
@en
Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII
@nl
type
label
Safety and Efficacy of B-domai ...... -marketing Surveillance Study.
@en
Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII
@nl
prefLabel
Safety and Efficacy of B-domai ...... -marketing Surveillance Study.
@en
Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII
@nl
P2093
P2860
P50
P921
P356
P1476
Safety and Efficacy of B-domai ...... -marketing Surveillance Study.
@en
P2093
Eun Jin Choi
Ki Young Yoo
Kun Soo Lee
Sang Kyu Park
Taiju Hwang
P2860
P356
10.3346/JKMS.2018.33.E5
P577
2018-01-01T00:00:00Z